IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting
December 11, 2021 13:31 ET
|
IGM Biosciences, Inc.
- Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and FL, and has a Favorable Safety Profile - - Phase...
IGM Biosciences to Collaborate on the Study of IgM and IgA Antibodies for the Prevention of Malaria
December 08, 2021 07:00 ET
|
IGM Biosciences, Inc.
– Grant Agreement with the Bill & Melinda Gates Foundation Aims to Leverage IGM’s Engineered IgM and IgA Antibodies to Address a Significant Driver of Morbidity and Mortality in Low- and...
IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 63rd Annual ASH Meeting
December 06, 2021 16:05 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Jefferies London Healthcare Conference
November 10, 2021 16:05 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference
November 08, 2021 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 04, 2021 09:21 ET
|
IGM Biosciences, Inc.
– Plans to Initiate Phase 2 Studies of IGM-2323 in Diffuse Large B-cell Lymphoma and Follicular Lymphoma – – Data from IGM-2323 Selected for Oral Presentation at 2021 ASH Annual Meeting – – IGM-8444...
IGM Biosciences Announces Leadership Appointments and Formation of IGM Infectious Diseases and IGM Autoimmunity and Inflammation Business Units
October 11, 2021 16:05 ET
|
IGM Biosciences, Inc.
– John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases – – Mary Beth Harler, M.D., Appointed...
IGM Biosciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 23, 2021 16:05 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Participate in Three Upcoming Investor Conferences
September 07, 2021 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 09, 2021 16:06 ET
|
IGM Biosciences, Inc.
– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – Expansion of IgM Platform into Infectious Diseases – ...